UniQure N.V. (QURE) Upgraded to Overweight as Huntington’s Disease Program Advances
TheFly reported on June 18 that Barclays raised its rating on QURE to Overweight from Equal Weight and increased its price target to $65 from $25.
Uniqure N.v. (QURE)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 6,727,777 | $309,881,409 | +13% | 2.78% |
| 2. | OrbiMed Advisors Samuel Isaly | 1,807,486 | $83,252,805 | -16% | 1.54% |
| 3. | Boxer Capital Aaron Davis And Christopher Fuglesang | 1,503,300 | $69,241,998 | +128% | 5.21% |
| 4. | Two Seas Capital Sina Toussi | 1,441,410 | $66,391,345 | +11% | 1.31% |
| 5. | MAK Capital One Michael Kaufman | 1,232,051 | $56,748,269 | +180% | 7.95% |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $45.89 | 7,600 | $348,764.00 | 519,227 | 2026-07-02 | Filing | |
| $45.43 | 4,282 | $194,531.26 | 526,827 | 2026-07-02 | Filing | |
| $44.43 | 9,200 | $408,756.00 | 531,109 | 2026-07-02 | Filing | |
| $46.40 | 20,000 | $928,000.00 | 148,235 | 2026-06-30 | Filing | |
| $46.46 | 10,000 | $464,600.00 | 168,235 | 2026-06-30 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,867,755 | $230,813,250 | 0.01% | |
| 2. | 3,941,572 | $181,548,806 | 1.55% | |
| 3. | 2,903,825 | $133,750,180 | 0% | |
| 4. | 2,848,117 | $131,184,269 | 0.18% | |
| 5. | 2,577,700 | $118,728,862 | 0.01% |
News See All
10 Best Healthcare Stocks to Buy According to Wall Street Analysts
The U.S. healthcare sector has significantly lagged the broader market for three consecutive years, returning just 0.3% in 2023, 0.9% in 2024, and 12.5% in 2025.
10 Best Gene Therapy Stocks to Buy in 2026
Gene therapies aim to treat or prevent diseases by introducing new instructions in a patient’s cells to fix or replace the defective genes behind genetic disorders.
Is uniQure N.V. (QURE) A Good Stock To Buy Now?
Is QURE a good stock to buy? We came across a bullish thesis on uniQure N.V. on r/stocks by AntoniaFauci. In this article, we will summarize the bulls’ thesis on QURE.
10 Best Small-Cap Biotech Stocks to Buy According to Hedge Funds
On February 16, Franklin Equity said the biotechnology industry has entered 2026 on a firmer footing following an extended period of market uncertainty in the prior year, noting that market attention ...
7 Best Small-Cap Healthcare Stocks to Buy According to Hedge Funds
In this article, we will look at the best small-cap healthcare stocks to buy according to hedge funds.
uniQure N.V. (NASDAQ:QURE) Q4 2025 Earnings Call Transcript
Operator: Thank you for standing by. My name is Kate, and I will be your conference operator today.
Wolfe Research Initiates Coverage of UniQure (QURE) With a Peer Perform Rating
UniQure (NASDAQ:QURE) is one of the top gene therapy stocks to buy according to hedge funds.
Top 10 Gene Therapy Stocks to Buy According to Hedge Funds
On February 23, Lauren Goodwin, New York Life Investments, appeared on CNBC’s ‘Closing Bell’ to talk about the state of equity markets and tariff uncertainties.
Hedge Fund Resource Center